SPT — Investor Presentation 2021

Aug 11, 2021

1789 TT

ScinoPharm

August 11, 2021

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The information contained in this presentation is ScinoPharm’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty , express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to , the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks , uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

2

==> picture [82 x 26] intentionally omitted <==

Table of Content

 Business Overview

 Business Update

 Financial Performance

3

==> picture [720 x 88] intentionally omitted <==

Business Overview

4

Stable USD Sales Growth amid Covid-19

• Supply chain change caused by on-going covid-19 pandemic

• Global logistic striving for recovery

• Customer inventory adjustment

• Taiwan level 3 covid-19 alert in 2Q

• Dynamic production and sales planning to adapt the challenge

• 2021 1H revenue in USD increased 2.1%, yoy

 Due to strong NTD, consolidated revenue was NTD 1,389 million, down 4.3% yoy, with NPAT NTD 181 million, down 8.1% yoy, and NPAT margin 13.0%

5

Strengthen Generic API Business Expand China & Japan Market

 Leverage Tainan/Changshu production advantage with better sales/production coordination to stably supply Japan & China markets

• CFDI’s on-site inspection on Changshu site

• Inspection for Donafenib and Bimatoprost completed in 2021 1H

• 1 on-site inspections scheduled in 2021 2H

• 2 customers launched the products after CFDI approval

• 2 CDMO customers obtained approval for Donafenib and Camcevi in China & USA – shipment accommodating launch time; Eflornithine submitted to FDA and EMA by CDMO customer

6

Changshu Milestone for Upside

• Collaborate with customers to complete CFDI’s on-site inspection for their approvals of product launch in China market

• Operations on track for upside

Develop Injectables for future growth

• Profit-sharing from drug products (in-house development + outsourcing production), and various drug products development in progress

• Following the 1[st] in-house prefilled-syringe product, an in-house liquid solution product was submitted to FDA for ANDA

• Completed the 1[st] TFDA on-site inspection in April, 2021

7

==> picture [720 x 88] intentionally omitted <==

Business Update

8

==> picture [161 x 150] intentionally omitted <==

----- Start of picture text -----

Optimize
Generic API
Portfolio
----- End of picture text -----

 Generic API Business Update

 Leverage Tainan/Changshu production advantage and strengthen sales/production coordination to stabilize supply  The impact of Covid-19 pandemic  Generic API Portfolio

==> picture [498 x 238] intentionally omitted <==

----- Start of picture text -----

38
40 Data as of 2021/06/30
35
Pipeline
30 Approved
20
25
20
12
15
10 18 7 6 6
5 4 2 3 2 2 2 2 1
5 2 4 3 2 11 2 2 1
0
----- End of picture text -----

==> picture [35 x 33] intentionally omitted <==

==> picture [378 x 58] intentionally omitted <==

9

==> picture [161 x 150] intentionally omitted <==

----- Start of picture text -----

Optimize
Generic API
Portfolio
----- End of picture text -----

 2021 Generic API Product A roval Plan pp

Type	Product	Region	Indication	Brand Marketer
Generic API	Fondaparinux Sodium	CN( )	Anti-thrombotic	Mylan
Generic API	Irinotecan HCl	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Sodium Phenylbutyrate	CN( )	Urea cycle disorders	Horizon Therapeutics
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Letrozole	CN	Breast cancer	Novartis
Generic API	Bimatoprost	CN	Glaucoma	Allergan
Generic API	Regadenoaon	US	MPI	Astellas
Generic API	＊Pemetrexed Disodium 7H2O CEP	EU	Non-small cell lung cancer	Eli Lilly
Generic API	Topiramate	EU	Weight management	Vivus
：Approved ＊：Collaborative project for drug product development Data as of 2021/06/30

10

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Expand
CDMO
Business
----- End of picture text -----

 CDMO Business

==> picture [367 x 343] intentionally omitted <==

----- Start of picture text -----

12
11
12
9
10
6
1
6
8
6
6
8
4
6 6
5
2
0
Phase 1 Phase 2 Phase 3 Commercial
----- End of picture text -----

==> picture [116 x 33] intentionally omitted <==

----- Start of picture text -----

SciAnda (Changshu)
ScinoPharm Taiwan
----- End of picture text -----

Data as of 2021/06/30

11

Expand CDMO Business	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan	2021 CDMO API Product Approval Plan
	Type	Product	Region	Indication	Brand Marketer
	CDMO API	Donafenib	CN( )	Cancer	Suzhou Zelgen
	CDMO API	Camcevi	US( ) EU	Cancer	Foresee
	CDMO API	Eflornithine	US/EU	FAP	CPP

Data as of 2021/06/30

• Donafenib (NCE) was approved and launched in China in June, 2021

• Camcevi (NCE) was approved by FDA in June, 2021; MAA review in progress

• Eflornithine submitted to FDA and EMA by customer

12

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Advancing
to
Injectables
----- End of picture text -----

==> picture [127 x 100] intentionally omitted <==

Peptides

==> picture [132 x 114] intentionally omitted <==

==> picture [134 x 114] intentionally omitted <==

Sterile Injectables Pen Injectors

• Profit-sharing from 3 drug products (in-house development + outsourcing production)

• ANDA of 1[st] in-house prefilled-syringe product was submitted to FDA in May, 2020 - Response to FDA in progress

• ANDA of 1[st] in-house liquid solution product was submitted to FDA in June, 2021

• Registration batches of Vial line (prefilled-syringed /pen device) and Cartridge line (liquid solution/ lyophilized powder) products were completed

• Completed the 1[st] TFDA on-site inspection in April, 2021, official inspection report received in June and replied in July, TFDA’s review in progress

13

==> picture [222 x 144] intentionally omitted <==

----- Start of picture text -----

Actively Develop
Japan, China and
Emerging Markets
----- End of picture text -----

 Japan Market

• The impact of Covid-19 pandemic

• The largest generic API supplier for Galantamine HBr and Capecitabine in Japan

• Indication： Alzheimer’s disease / Various cancers

• ：

• Japan market size c. USD 200 million / over USD 100 million

 Leverage Japan’s late patent expiration and our new injectables capacity to explore opportunities for generic APIs + CDMO projects

14

==> picture [222 x 143] intentionally omitted <==

----- Start of picture text -----

Actively Develop
Japan, China and
Emerging Markets
----- End of picture text -----

 China Market

• Customer’s Fondaparinux Sodium PFS launched in Feb. 2021  Indication：Anti-thrombotic

• Market Size：c. RMB 200 million

• CFDI on-site ins ection in Chan shu site p g

Inspection Product Approval Indication Market Sodium Urea cycle 2020.09 2021.05 Urea cycle disorders Phenylbutyrate disorders Advanced liver 1[st] year sales projected 2021.02 Donafenib 2021.06 cancer firstby research report： line treatment c. RMB 220 million Expect in 2021.06 Bimatoprost year-end Glaucoma c. RMB 1 billion of 2021

• Changshu site expects to activate one more inspections in 2021

15

==> picture [720 x 88] intentionally omitted <==

Financial Performance

16

Consolidated Income Statement

In NTD Million, except for EPS	1H 2021 (Reviewed)	1H 2021 (Reviewed)	YoY	1H 2020 (Reviewed)	1H 2020 (Reviewed)
Revenue	1,389	100%	-4%	**1,451 **	100%
Gross Profit	702	51%	3%	682	47%
Operating Profit	221	16%	-12%	252	17%
Net Profit before Tax	224	16%	-11%	252	17%
Net Profit after Tax	181	13%	-8%	197	14%
EPS (NTD)	0.23	-	-	0.25	-

17

1H 2021 Sales Distribution

==> picture [672 x 227] intentionally omitted <==

----- Start of picture text -----

Drug
CDMO India China Others
Product
13% 4% 6% 10%
4%
US+Canada
Generic
Japan 25%
API 30%
EU
83%
25%
Others
by Business CNS
7% by Region
26%
----- End of picture text -----

by Indication

18

Sales Distribution – YoY

By Business Unit: USD Generic API CDMO Drug Product 1H 2021 Sales 41.0M 6.3M 2.0M YoY 4.9% -27.6% 276.9%

By Business

By Indication

Oncology CNS Others 1H 2021 Sales 33.0M 12.9M 3.4M YoY -3.9% 19.2% 9.2% By Region US & EU Japan India China Others Canada 1H 2021 Sales 12.1M 12.2M 14.8M 1.9M 3.2M 5.1M YoY -30.5% 9.9% 81.3% -74.4% 253.6% 54.0%

By Region

19

Consolidated Balance Sheet

In NTD Million	2021/6/30 (Reviewed)	2021/6/30 (Reviewed)	2020/6/30 (Reviewed)	2020/6/30 (Reviewed)
Cash and Cash Equivalents	4,104	34%	3,803	31%
Accounts Receivable	355	3%	554	5%
Inventories	1,449	12%	1,299	11%
Property, Plant & Equipment	4,100	34%	4,255	35%
Other Current/Non-Current Assets	2,070	17%	2,197	18%
Total Assets	12,078	100%	12,108	100%
Financial Debt	40	0%	261	2%
Other Current Liabilities	1,027	9%	830	7%
Other Non-Current Liabilities	626	5%	636	5%
Total Liabilities	1,693	14%	1,727	14%
Total Shareholders' Equities	10,385	86%	10,381	86%

20

Consolidated Cash Flow Statement

==> picture [634 x 393] intentionally omitted <==

----- Start of picture text -----

1H 2021 1H 2020
In NTD million
(Reviewed) (Reviewed)
From Operating Activities 180 368
From Investing Activities (152) 123
From Financing Activities 27 29
Effect of foreign exchange rate changes (6) (22)
Net Change in Cash 49 498
Beginning Balance 4,055 3,305
Ending Balance 4,104 3,803
----- End of picture text -----

21

==> picture [720 x 88] intentionally omitted <==

Q & A

22

==> picture [720 x 88] intentionally omitted <==

Appendix Company Overview

23

ScinoPharm at a Glance

• Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan and Changshu and marketing forces in Tainan, Shanghai and Tokyo

• Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide

• 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*

• 874 active DMFs worldwide with 64 US DMFs*

• 150+ contract projects with 8 approved/launched (6 NCEs) and 7 in phase 3 for NDA/MAA filing in 1-3 years*

 Certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority

• Data as of 2021/06/30

24

==> picture [81 x 27] intentionally omitted <==

==> picture [676 x 127] intentionally omitted <==

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT

25